Drug or treatment

Brentuximab clinical trials

• 17Clinical trials
• 17Countries

Newest trials

All recruiting trials (17)

• Brentuximab Vedotin plus CHP as first-line therapy for CD30-positive peripheral T-cell lymphoma in Spain

  This study looks at how safe and effective BV-CHP is when used as the first treatment for adults with CD30-positive peripheral T-cell lymphoma in real-world Spanish clinical care.

  Recruiting at 37 sites Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · A Coruña, A Coruña and 36 other locations · NCT07624838

• Chidamide plus brentuximab vedotin for CD30-positive peripheral T‑cell lymphoma in patients unfit for chemotherapy

  This treatment will test whether combining chidamide with brentuximab vedotin helps people with CD30-positive peripheral T‑cell lymphoma who cannot tolerate standard chemotherapy.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07074457

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Using Brentuximab Vedotin to treat newly diagnosed Classical Hodgkin Lymphoma in young patients

  This study is testing if a new treatment with Brentuximab vedotin can help young patients with newly diagnosed classical Hodgkin lymphoma feel better while reducing the need for chemotherapy and radiation.

  Recruiting Phase 2/3 Children's Cancer Group, China · Shanghai · NCT06563245

• Comparing standard therapy to immunotherapy for early stage Hodgkin lymphoma

  This study is testing if adding immunotherapy to standard chemotherapy helps people with early stage Hodgkin lymphoma live longer and stay cancer-free.

  Recruiting at 404 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 418 other locations · NCT05675410

• New treatment approach for relapsed or refractory Hodgkin lymphoma

  This study is testing a new treatment for people with relapsed or hard-to-treat Hodgkin lymphoma to see if combining certain therapies can help them live longer and feel better.

  Recruiting Phase 2/3 Hospital Regional de Alta Especialidad del Bajio · León, Guanajuato · NCT05595447

• Survey of Brentuximab Vedotin for treating pediatric Hodgkin Lymphoma

  This study looks at how well Brentuximab Vedotin works with standard treatment for kids with Hodgkin lymphoma and checks for any side effects they might have.

  Recruiting Takeda · Tokyo, Tokyo · NCT05481437

• Combining low-dose radiation therapy with brentuximab vedotin for mycosis fungoides

  This study is testing if combining a low-dose radiation treatment with a medication called brentuximab vedotin can help people with mycosis fungoides, a type of skin lymphoma, feel better and improve their overall health.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05357794

• Combination of pembrolizumab and brentuximab for relapsed T-cell lymphoma

  This study is testing if a combination of two drugs, pembrolizumab and brentuximab, can help people with relapsed T-cell lymphoma feel better after other treatments haven't worked.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT05313243

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Combination treatment of brentuximab vedotin and nivolumab for relapsed Hodgkin lymphoma

  This study is testing if combining two treatments, brentuximab vedotin and nivolumab, can help people with relapsed Hodgkin lymphoma who haven't responded well to previous therapies.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT05039073

• Treatment for Primary Mediastinal Large B-cell Lymphoma with Antibody Therapy and ImmunoChemotherapy

  This study is testing a new combination of antibody therapy and chemotherapy to see if it helps people with untreated primary mediastinal large B-cell lymphoma feel better and improve their quality of life.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04745949

• Brentuximab vedotin for early stage Hodgkin lymphoma treatment

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help people with early-stage Hodgkin lymphoma do better in their treatment.

  Recruiting at 72 sites Phase 3 University College, London · Stanford, California and 71 other locations · NCT04685616

• Combining brentuximab vedotin and bendamustine for treating relapsed or refractory follicular lymphoma

  This study is testing if combining two drugs, brentuximab vedotin and bendamustine, can help people with relapsed or hard-to-treat follicular lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT04587687

• Treatment for relapsed or refractory classical Hodgkin lymphoma using brentuximab vedotin and nivolumab

  This study is testing a combination of two drugs, brentuximab vedotin and nivolumab, to see if they can help people with classical Hodgkin lymphoma that has come back or didn’t respond to previous treatments.

  Recruiting at 5 sites Phase 2 City of Hope Medical Center · Duarte, California and 4 other locations · NCT04561206

• Treatment for CD30 Positive Diffuse Large B-cell Lymphoma Patients Who Didn't Respond to Initial Chemotherapy

  This study is testing a new treatment combining brentuximab vedotin and chemotherapy for patients with CD30 positive diffuse large B-cell lymphoma who didn't respond to their first chemotherapy, to see if it can improve their chances of recovery.

  Recruiting Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Rotterdam · NCT03356054

Quick answers

How many clinical trials of Brentuximab are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in United States (9 trials), Canada (3 trials), China (2 trials), Australia (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 2/3: 2, Phase 3: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →